Treatment and survival of patients with cancer of the prostate. The Veterans Administration Co-operative Urological Research Group.

Suppr

超能文献

出版信息

Surg Gynecol Obstet. 1967 May;124(5):1011-7.

PMID:6022476

Abstract

摘要

相似文献

Treatment and survival of patients with cancer of the prostate. The Veterans Administration Co-operative Urological Research Group.

Surg Gynecol Obstet. 1967 May;124(5):1011-7.

Treatment of prostatic cancer: studies by the Veterans Administration cooperative urological research group.

Bull N Y Acad Med. 1972 Jun;48(5):751-66.

Endocrine treatment of cancer of the prostate.

Wis Med J. 1970 Jul;69(7):177-81.

[Hormone therapy of cancer of the prostate gland].

Urol Nefrol (Mosk). 1970 May-Jun;35(3):25-8.

Cancer of the prostate.

N Engl J Med. 1968 Apr 11;278(15):848-9. doi: 10.1056/NEJM196804112781512.

Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma.

South Med J. 1977 Dec;70(12):1411-3.

Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies.

NCI Monogr. 1988(7):165-70.

[Treatment of clinically localized prostatic cancer--endocrine therapy].

Hinyokika Kiyo. 1996 Oct;42(10):829-32.

The Veterans' Administration Cooperative Urological Research Group studies of carcinoma of the prostate: a review.

Cancer Chemother Rep. 1975 Jan-Feb;59(1):225-7.

Correlation of pretreatment serum nonprotein-bound cortisol and total 17-hydroxycorticosteroid values with survival in patients with prostatic cancer.

N Engl J Med. 1974 Oct 10;291(15):751-5. doi: 10.1056/NEJM197410102911502.

引用本文的文献

The Pros and Cons of Estrogens in Prostate Cancer: An Update with a Focus on Phytoestrogens.

Biomedicines. 2024 Jul 23;12(8):1636. doi: 10.3390/biomedicines12081636.

Financial toxicity differences between chemical versus surgical androgen deprivation therapy.

Transl Androl Urol. 2022 Oct;11(10):1365-1367. doi: 10.21037/tau-22-588.

Translational Strategies to Target Metastatic Bone Disease.

Cells. 2022 Apr 12;11(8):1309. doi: 10.3390/cells11081309.

Evolution of Androgen Deprivation Therapy (ADT) and Its New Emerging Modalities in Prostate Cancer: An Update for Practicing Urologists, Clinicians and Medical Providers.

Res Rep Urol. 2022 Mar 30;14:87-108. doi: 10.2147/RRU.S303215. eCollection 2022.

The resurgence of estrogens in the treatment of castration-resistant prostate cancer.

Indian J Urol. 2019 Jul-Sep;35(3):189-196. doi: 10.4103/iju.IJU_56_19.

Fluorine-18 Labeled Fluorofuranylnorprogesterone ([F]FFNP) and Dihydrotestosterone ([F]FDHT) Prepared by "Fluorination on Sep-Pak" Method.

Molecules. 2019 Jun 28;24(13):2389. doi: 10.3390/molecules24132389.

Diethylstilbestrol in the Treatment of Castration-resistant Prostate Cancer: A Lower-middle-income Country Experience.

Cureus. 2019 Apr 16;11(4):e4470. doi: 10.7759/cureus.4470.

Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer.

Cochrane Database Syst Rev. 2019 Jun 11;6(6):CD003506. doi: 10.1002/14651858.CD003506.pub2.

Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression.

Nat Genet. 2018 Jun;50(6):814-824. doi: 10.1038/s41588-018-0120-1. Epub 2018 May 28.

Early use of chemotherapy in metastatic prostate cancer.

Cancer Treat Rev. 2017 Apr;55:218-224. doi: 10.1016/j.ctrv.2016.09.017. Epub 2016 Oct 3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验